Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

被引：2

作者：

Bhutani, Manisha ^{[1
]}

Robinson, Myra ^{[2
]}

Atrash, Shebli ^{[1
]}

Paul, Barry ^{[1
]}

Pineda-Roman, Mauricio ^{[1
]}

Foureau, David ^{[3
]}

Varga, Cindy ^{[1
]}

Friend, Reed ^{[1
]}

Begic, Xhevahire ^{[4
]}

Norek, Sarah ^{[4
]}

Drennan, Tiffany ^{[5
]}

Anderson, Michelle B. ^{[6
]}

Symanowski, James ^{[2
]}

Voorhees, Peter M. ^{[7
]}

Usmani, Saad Z. ^{[8
]}

机构：

[1] Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA

[2] Atrium Hlth, Levine Canc Inst, Dept Canc Biostat, Charlotte, NC USA

[3] Atrium Hlth, Levine Canc Inst, Immune Monitoring Core Lab, Charlotte, NC USA

[4] Atrium Hlth, Levine Canc Inst, Sponsored Res Coordinating Ctr, Charlotte, NC USA

[5] Atrium Hlth, Levine Canc Inst, Clin Trials Unit, Charlotte, NC USA

[6] Atrium Hlth, Levine Canc Inst, Biostat & Data Sci, Charlotte, NC USA

[7] Wake Forest Univ, Sch Med, Atrium Hlth, Dept Hematol Oncol & Blood Disorders,Levine Canc, Charlotte, NC USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174972

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN [J].

Nooka, Ajay K. ;

Kaufman, Jonathan L. ;

Rodriguez, Cesar ;

Jakubowiak, Andrzej ;

Shune, Leyla ;

Badros, Ashraf ;

Chari, Ajai ;

Richardson, Paul G. ;

Pei, Huiling ;

Ukropec, Jon ;

Vermeulen, Jessica ;

Hoehn, Daniela ;

Lin, Thomas S. ;

Voorhees, Peter M. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 :S308-S309

[22] Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial [J].

Costa, Luciano J. ;

Chhabra, Saurabh ;

Medvedova, Eva ;

Schmidt, Timothy Martin ;

Dholaria, Bhagirathbhai ;

Godby, Kelly N. ;

Silbermann, Rebecca ;

Bal, Susan ;

D'Souza, Anita ;

Giri, Smith ;

Omel, James L. ;

Hari, Parameswaran ;

Callander, Natalie ;

Dhakal, Binod .

BLOOD, 2022, 140 :7275-7277

[23] Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients [J].

Korde, Neha ;

Zingone, Adriana ;

Kwok, Mary ;

Manasanch, Elisabet E. ;

Costello, Rene ;

Zuchlinski, Diamond ;

Mulquin, Marcia ;

Maric, Irina ;

Calvo, Katherine R. ;

Braylan, Raul C. ;

Yuan, Constance ;

Tembhare, Prashant Ramesh ;

Stetler-Stevenson, Maryalice ;

Arthur, Diane C. ;

Raffeld, Mark ;

Xi, Liqiang ;

Choyke, Peter ;

Kurdziel, Karen ;

Lindenberg, Liza ;

Steinberg, Seth M. ;

Roschewski, Mark ;

Landgren, Ola .

BLOOD, 2012, 120 (21)

[24] Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) [J].

Zimmerman, Todd ;

Raje, Noopur S. ;

Vij, Ravi ;

Reece, Donna ;

Berdeja, Jesus G. ;

Stephens, Leonor A. ;

McDonnell, Kathryn ;

Rosenbaum, Cara A. ;

Jasielec, Jagoda ;

Richardson, Paul G. ;

Gurbuxani, Sandeep ;

Nam, Jennifer ;

Severson, Erica ;

Wolfe, Brittany D. ;

Rosebeck, Shaun ;

Stefka, Andrew ;

Dytfeld, Dominik ;

Griffith, Kent ;

Jakubowiak, Andrzej .

BLOOD, 2016, 128 (22)

[25] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia [J].

Bahlis, Nizar ;

Facon, Thierry ;

Usmani, Saad Z. ;

Kumar, Shaji K. ;

Plesner, Torben ;

Orlowski, Robert Z. ;

Touzeau, Cyrille ;

Basu, Supratik ;

Nahi, Hareth ;

Hulin, Cyrille ;

Quach, Hang ;

Goldschmidt, Hartmut ;

O'Dwyer, Michael E. ;

Venner, Christopher P. ;

Weisel, Katja C. ;

Krevvata, Maria ;

Pei, Huiling ;

Wang, Jianping ;

Van Rampelbergh, Rian ;

Ukropec, Jon ;

Uhlar, Clarissa M. ;

Kobos, Rachel ;

Perrot, Aurore .

BLOOD, 2019, 134

[26] INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) [J].

Zimmerman, T. M. ;

Griffith, K. ;

Jasielec, J. K. ;

Rosenbaum, C. A. ;

McDonnell, K. ;

Marin, J. ;

Bakker, J. ;

Berdeja, J. G. ;

Vij, R. ;

Jakubowiak, A. J. .

HAEMATOLOGICA, 2014, 99 :103-103

[27] Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial [J].

Jakubowiak, Andrzej J. ;

Dytfeld, Dominik ;

Jagannath, Sundar ;

Vesole, David H. ;

Anderson, Tara B. ;

Nordgren, Brian K. ;

Lebovic, Daniel ;

Stockerl-Goldstein, Keith E. ;

Griffith, Kent A. ;

Hill, Melissa A. ;

Harvey, Colleen K. ;

Dollard, Akari M. ;

Ott, Robert ;

Kelley, Susan L. ;

Barrickman, Jennifer ;

Kauffman, Michael ;

Vij, Ravi .

BLOOD, 2010, 116 (21) :376-377

[28] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD ResponseAdapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial [J].

Costa, Luciano J. ;

Chhabra, Saurabh ;

Callander, Natalie S. ;

Medvedova, Eva ;

Dholaria, Bhagirathbhai R. ;

Silbermann, Rebecca W. ;

Godby, Kelly N. ;

Dhakai, Binod ;

Bai, Susan ;

Gin, Smith ;

Souza, Anitad ;

Schmidt, Timothy M. ;

Hall, Aric C. ;

Hardwick, Pamela ;

Cornell, Robert F. ;

Hari, Parameswaran .

BLOOD, 2021, 138

[29] MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma [J].

Bhutani, Manisha ;

Robinson, Myra ;

Foureau, David ;

Atrash, Shebli ;

Paul, Barry ;

Guo, Fei ;

Grayson, Jason M. ;

Ivanina-Foureau, Anna ;

Pineda-Roman, Mauricio ;

Varga, Cindy ;

Friend, Reed ;

Ferreri, Christopher J. ;

Begic, Xhevahire ;

Norek, Sarah ;

Drennan, Tiffany ;

Anderson, Michelle B. ;

Symanowski, James T. ;

Voorhees, Peter M. ;

Usmani, Saad Z. .

BLOOD ADVANCES, 2025, 9 (03) :507-519

[30] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. [J].

Rodriguez-Otero, Paula ;

Moreau, Philippe ;

Dimopoulos, Meletios Athanasios ;

Beksac, Meral ;

Perrot, Aurore ;

Broijl, Annemiek ;

Gay, Francesca ;

Mina, Roberto ;

van de Donk, Niels W. C. J. ;

Schjesvold, Fredrik ;

Delforge, Michel ;

Einsele, Hermann ;

Spencer, Andrew ;

Lonergan, Sarah ;

Vieyra, Diego ;

Sitthi-Amorn, Anna ;

Carson, Robin L. ;

Blade, Joan ;

Boccadoro, Mario ;

Sonneveld, Pieter .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →